Pediatrix Medical Group, Inc. (NYSE:MD) Receives $10.90 Average Price Target from Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has been given a consensus rating of “Hold” by the five research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $10.90.

A number of research analysts recently weighed in on MD shares. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. UBS Group increased their price objective on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their target price for the stock from $8.00 to $14.00 in a research note on Thursday, September 26th.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its stake in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. boosted its position in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares during the period. Boston Partners boosted its position in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter worth about $1,721,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 0.2 %

MD stock opened at $12.73 on Thursday. The stock has a fifty day moving average of $11.20 and a 200-day moving average of $9.18. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $12.99. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -14.98, a PEG ratio of 1.91 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm had revenue of $504.30 million during the quarter, compared to analyst estimates of $505.49 million. During the same quarter last year, the business earned $0.37 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. As a group, equities research analysts predict that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.